UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

__________________________

FORM 6-K

__________________________

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the month of: January 2023
(Report No. 2)

Commission file number: 001-39674

__________________________

G MEDICAL INNOVATIONS HOLDINGS LTD.
(Translation of registrant’s name into English)

__________________________

5 Oppenheimer St.
Rehovot 7670105, Israel
(Address of principal executive offices)

__________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated by reference herein are the Notice of Extraordinary General Meeting of Shareholders, Notice Regarding the Availability of Proxy Materials, Proxy Statement and Proxy Card for the Extraordinary General Meeting of Shareholders of G Medical Innovations Holdings Ltd. (the “Company”) to be held on Thursday, February 9, 2023 (the “Meeting”).

Only shareholders of record who hold ordinary shares, par value $3.15 per share, of the Company at the close of business on Tuesday, January 17, 2023, will be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-266090) and on Form S-8 (File No. 333-266063) of the Company, filed with the U.S. Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.
99.1		Notice and Proxy Statement for the Extraordinary General Meeting of Shareholders to be held on February 9, 2023.
99.2		Form of Proxy Card for the Extraordinary General Meeting of Shareholders to be held on February 9, 2023.
99.3		Important Notice Regarding the Availability of Proxy Materials for the Extraordinary General Meeting to be held on February 9, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	G Medical Innovations Holdings Ltd.
Date: January 24, 2023	By	/s/ Yacov Geva
	Name:	Yacov Geva
	Title:	Chief Executive Officer